AKESO Shares Climb Nearly 3% on Positive Phase II Data for Cadonilimab Combo in Pancreatic Cancer

Stock News04-22 10:36

AKESO (09926) saw its shares rise by nearly 3%. As of the time of writing, the stock was up 2.66%, trading at HK$150.6 with a turnover of HK$613 million. The increase follows the company's announcement on its official social media account that significant data from the Phase II clinical trial (COMPASSION-26) of its globally first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with chemotherapy as a first-line treatment for advanced pancreatic cancer (PDAC), was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Study results indicated that the cadonilimab combination regimen demonstrated promising anti-tumor activity and survival benefits in patients with advanced pancreatic cancer. Notably, in patients with locally advanced, inoperable disease, the median overall survival (OS) reached 23.4 months and the median progression-free survival (PFS) reached 11.1 months.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment